FDA Panel Votes to Add Peptides to Compounding List

FDA Committee Votes in Favor of Allowing Compounding Pharmacies to Produce Certain Peptides

In a move that has raised eyebrows, the Food and Drug Administration's (FDA) Pharmacy Compounding Advisory Committee (PCAC) has voted in favor of adding peptides to the list of substances that compounding pharmacies can manufacture. This decision comes despite concerns from agency scientists and experts regarding the lack of demonstrated benefits and potential risks associated with these compounds. The committee's vote, which took place on Thursday, marked a departure from the views of FDA scientists who had expressed concerns about the peptides in question.

The peptides at the center of the debate include BPC-157, KPV, TB-500, and MOTS-c, which have been touted for their potential therapeutic benefits. However, the FDA's own scientists have questioned the efficacy of these compounds, citing a lack of robust clinical data to support their use. During the committee's meeting, agency staffers presented their findings, and the public was given the opportunity to provide comments. Despite these concerns, the PCAC ultimately voted in favor of allowing compounding pharmacies to produce these peptides, paving the way for their potential use in the treatment of various medical conditions.

The FDA's decision to permit the production of these peptides has sparked debate among experts and raises questions about the agency's regulatory approach. While some see this as a step towards increasing access to innovative treatments, others are concerned about the potential risks associated with these compounds. The FDA will now consider the PCAC's recommendations and make a final determination on the matter.